Concert Pharmaceuticals shares have continued to sell off following last week's negative AVP-786 data and currently trade near the company's cash value of $5, Mizuho analyst Difei Yang tells investors in a research note. The analyst, however, continues to see "significant value" in Concert's clinical pipeline. CTP-543 remains a key value driver, and earlier-stage asset CTP-692, for the adjunctive treatment of schizophrenia, is set to enter Phase 2 in Q4 and offers additional potential upside, says Yang. The analyst reiterates a Buy rating on Concert Pharmaceuticals.